JBiSE  Vol.4 No.5 , May 2011
Enhanced stability of nano-emulsified paclitaxel
ABSTRACT
The main goal of this work was to develop an optimal self-microemulsifying paclitaxel prepared with PLGA and solubilizer such as tetraglycol, Cremophor ELP, and Labrasol. The prepared PTx-loaded SMES showed the size of the range of 80–130 nm by dy-namic light scattering and a spherical shape by atomic force microscopy. In experiment of storage stability in deionized water (DW) or blood condition, PTx-loaded SMES showed good stability in DW and comparable stability in blood condition at 37oC for 7 days. In addition, PTx-loaded SMES showed a sig-nificant inhibitory effect on B16F10 melanoma proli-feration. In conclusion, we confirmed that the for-mulations tried in this study could be used as admin-istration form for animal trials of PTx.

Cite this paper
nullLee, J. , Kim, D. , Kim, G. , Kang, K. , Min, B. , Lee, B. , Kim, J. and Kim, M. (2011) Enhanced stability of nano-emulsified paclitaxel. Journal of Biomedical Science and Engineering, 4, 352-356. doi: 10.4236/jbise.2011.45044.
References
[1]   Li, J.Y., Strobel, G., Sidhu, R., Hess, W.M. and Ford, E.J. (1996) Endophytic taxol-producing fungi from bald cypress, Taxodium distichum. Microbiology, 142, 2223- 2226. doi:10.1099/13500872-142-8-2223

[2]   Spencer, C.M. and Faulds, D. (1994) Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48, 794-847.

[3]   Scripture, C.D., Szebeni, J., Loos, W.J., Figg, W.D. and Sparreboom, A. (2005) Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). Cancer Biology & Therapy, 4, 555-560.

[4]   Cordes, N. and Plasswilm, L. (1998) Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): Role of the solvent Cremophor EL/ethanol. Anticancer Research, 18, 1851-1857.

[5]   Pang, K.S., Maeng, H.J. and Fan, J. (2009) Interplay of transporters and enzymes in drug and metabolite processing. Molecular Pharmaceutics, 6, 1734-1755. doi:10.1021/mp900258z

[6]   Zhang, C., Qu, G., Sun, Y., Wu, X., Yao, Z., Guo, Q., Ding, Q., Yuan, S., Shen, Z., Ping, Q. and Zhou, H. (2008) Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials, 29, 1233-1241. doi:10.1016/j.biomaterials.2007.11.029

[7]   Wei, H., Cheng, S.X., Zhang, X.Z. and Zhuo, R.X. (2009) Thermo-sensitive polymeric micelles based on poly (N-isopropylacrylamide) as drug carriers. Progress in Polymer Science, 34, 893-910. doi:10.1016/j.progpolymsci.2009.05.002

[8]   Lee, H.B., Jeong, J.K., Sohn, S.I., Byun, Y., Ki, M.H. and Seo, J.K. (2009) Drug delivery and regenerative medicine technology. Tissue Engineering Regenerative Medicine, 4, 663-667.

[9]   Yu, W. and Zhang, N. (2009) Surface modification of nanocarriers for cancer therapy. Current Nanoscience, 5, 123-134. doi:10.2174/157341309788185370

[10]   Feng, S. and Huang, G. (2001) Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. Journal of Controlled Release, 71, 53-69. doi:10.1016/S0168-3659(00)00364-3

[11]   Gao, P., Rush, B.D., Pfund, W.P., Huang, T., Bauer, J.M., Morozowich, W., Kuo, M.S. and Hageman, M.J. (2003) Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. Journal of Pharmaceutical Sciences, 92, 2386-2398. doi:10.1002/jps.10511

[12]   Gursoy, N., Garrigue, J.S., Razafindratsita, A., Lambert, G. and Benita, S. (2003) Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. Journal of Pharmaceutical Sciences, 92, 2411-2418. doi:10.1002/jps.10501

[13]   Ten Tije, A.J., Verweij, J., Loos, W.J. and Sparreboom, A. (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clinical Pharmacokinetics, 42, 665-685.

[14]   Kan, P., Chen, Z.B., Lee, C.J. and Chu, I.M. (1999) Development of nonionic surfactant/phospholipid o/w emul- sion as a paclitaxel delivery system. Journal of Controlled Release, 58, 271-278. doi:10.1016/S0168-3659(98)00164-3

 
 
Top